Search Results - "Ramey, Dena R"

Excess healthcare resource utilization and costs for commercially insured patients with pulmonary arterial hypertension: A real‐world data analysis by Weiss, Tracey, Ramey, Dena R., Pham, Ngan, Shaikh, Nazneen Fatima, Tian, Dajun, Zhao, Xiaohui, Near, Aimee M., Lautsch, Dominik, Nathan, Steven D.

“…This retrospective study was conducted to evaluate all‐cause healthcare resource utilization (HCRU) and costs in commercially insured patients living with…”
Get full text

Real-world data to assess changes in low-density lipoprotein cholesterol and predicted cardiovascular risk after ezetimibe discontinuation post reporting of the Ezetimibe and Simvastatin in Hypercholesterolemia Enhances Atherosclerosis Regression trial by Bays, Harold E., MD, Patel, Mehul D., PhD, Mavros, Panagiotis, PhD, Ramey, Dena R., BA, Tomassini, Joanne E., PhD, Tershakovec, Andrew M., MD, MPH, Baxter, Carl A., PhD

“…Background The 2008 Ezetimibe and Simvastatin in Hypercholesterolemia Enhances Atherosclerosis Regression (ENHANCE) study demonstrated ezetimibe + simvastatin…”
Get full text

Impact of Switching From High-Efficacy Lipid-Lowering Therapies to Generic Simvastatin on LDL-C Levels and LDL-C Goal Attainment Among High-Risk Primary and Secondary Prevention Populations in the United Kingdom by Cao, Xiting, PhD, Ejzykowicz, Flavia, PhD, Ramey, Dena R., BS, Sajjan, Shiva, PhD, Ambegaonkar, Baishali M., PhD, Mavros, Panagiotis, PhD, Tunceli, Kaan, PhD

“…Abstract Purpose High cholesterol, especially high low-density lipoprotein cholesterol (LDL-C), is an important risk factor for cardiovascular disease (CVD)…”
Get full text

Therapeutic practice patterns related to statin potency and ezetimibe/simvastatin combination therapies in lowering LDL-C in patients with high-risk cardiovascular disease by Toth, Peter P., MD, PhD, Foody, JoAnne M., MD, Tomassini, Joanne E., PhD, Sajjan, Shiva G., PhD, Ramey, Dena R., BS, Neff, David R., DO, Tershakovec, Andrew M., MD, MPH, Hu, X. Henry, MD, PhD, Tunceli, Kaan, PhD

“…Background Statin combination therapy and statin uptitration have been shown to be efficacious in low-density lipoprotein cholesterol (LDL-C) lowering and are…”
Get full text

Treatment pattern changes in high-risk patients newly initiated on statin monotherapy in a managed care setting by Simpson, Ross J., MD, PhD, Tunceli, Kaan, PhD, Ramey, Dena R., BS, Neff, David R., DO, Kern, David M., MS, Hsieh, Hui-Min, PhD, Wertz, Debra A., PharmD, Stephenson, Judith J., SM, Marrett, Elizabeth, MPH, Tomassini, Joanne E., PhD, Jacobson, Terry A., MD

“…Back ground For high-risk patients who do not achieve guideline-recommended LDL-C levels, more intensive treatment including statin-uptitration to higher doses…”
Get full text

Skin improvement is a surrogate for favourable changes in other organ systems in early diffuse cutaneous systemic sclerosis by Nevskaya, Tatiana, Zheng, Boyang, Baxter, Carl A, Ramey, Dena R, Pope, Janet E, Baron, Murray

“…Abstract Objectives Skin improvement in diffuse cutaneous SSc (dcSSc), measured with modified Rodnan skin score (mRSS), is frequently used as a primary outcome…”
Get full text

Changes in skin score in early diffuse cutaneous systemic sclerosis are associated with changes in global disease severity by Zheng, Boyang, Nevskaya, Tatiana, Baxter, Carl A, Ramey, Dena R, Pope, Janet E, Baron, Murray

“…Abstract Objective To determine whether skin score changes are associated with changes in overall disease severity, function and quality of life in early dcSSc…”
Get full text

Post-switch Effectiveness of Etanercept Biosimilar Versus Continued Etanercept in Rheumatoid Arthritis Patients with Stable Disease: A Prospective Multinational Observational Study by Pope, Janet, Hall, Stephen, Bombardier, Claire, Haraoui, Boulos, Jones, Graeme, Naik, Latha, Etzel, Carol J., Ramey, Dena R., Infante, Ricardo, Miguelez, Maia, Falcao, Stephanie, Sahakian, Sevag, Wu, David

“…Introduction To better inform clinicians about the use of etanercept biosimilar (SB4) in patients with rheumatoid arthritis (RA), COMPANION-B, a prospective…”
Get full text

Loss of early gains in low-density lipoprotein cholesterol goal attainment among high-risk patients by Foody, JoAnne M., MD, FACC, FAHA, Sajjan, Shiva G., PhD, Hu, X. Henry, MD, PhD, Ramey, Dena R., BA, Neff, David R., DO, Tershakovec, Andrew M., MD, MPH, Tomassini, Joanne E., PhD, Wentworth, Chuck, BS, Tunceli, Kaan, PhD

“…Background Guidelines recommend a low-density lipoprotein cholesterol (LDL-C) measurement of <70 mg/dL as a reasonable goal in high-risk patients with coronary…”
Get full text

Switching from high-efficacy lipid-lowering therapies to simvastatin and low-density lipoprotein cholesterol goal attainment in coronary heart disease/coronary heart disease-equivalent patients by Tunceli, Kaan, PhD, Sajjan, Shiva G., PhD, Ramey, Dena R., BA, Neff, David R., DO, Tershakovec, Andrew M., MD, MPH, Hu, X. Henry, MD, PhD, Tomassini, Joanne E., PhD, Foody, JoAnne M., MD

“…Background The availability of generic simvastatin in 2006 has prompted substantial changes in formulary recommendations for lipid-management agents. Objective…”
Get full text

Gender Disparities in Lipid-Lowering Therapy in Cardiovascular Disease: Insights from a Managed Care Population by Rodriguez, Fatima, Olufade, Temitope O, Ramey, Dena R, Friedman, Howard S, Navaratnam, Prakash, Heithoff, Kim, Foody, JoAnne M

“…Numerous studies have documented the strong inverse relationship between low-density lipoprotein cholesterol (LDL-C) levels and atherosclerotic cardiovascular…”
Get more information

Plasma sitosterol elevations are associated with an increased incidence of coronary events in men: Results of a nested case-control analysis of the Prospective Cardiovascular Münster (PROCAM) study by Assmann, Gerd, Cullen, Paul, Erbey, John, Ramey, Dena R., Kannenberg, Frank, Schulte, Helmut

“…Sitosterolemia, a rare genetic disorder characterized by profoundly elevated plasma sitosterol concentrations, is associated with premature atherosclerosis in…”
Get full text

A Gene Expression Signature That Classifies Human Atherosclerotic Plaque by Relative Inflammation Status by Puig, Oscar, Yuan, Jeffrey, Stepaniants, Sergey, Zieba, Renata, Zycband, Emanuel, Morris, Mark, Coulter, Silvija, Yu, Xiang, Menke, John, Woods, John, Chen, Fabian, Ramey, Dena R, He, Xuanmin, OʼNeill, Edward A, Hailman, Eric, Johns, Douglas G, Hubbard, Brian K, Yee Lum, Pek, Wright, Samuel D, DeSouza, Mary M, Plump, Andrew, Reiser, Vladimír

“…BACKGROUND—Atherosclerosis is a complex disease requiring improvements in diagnostic techniques and therapeutic treatments. Both improvements will be…”
Get full text

Effects of ezetimibe, simvastatin, atorvastatin, and ezetimibe-statin therapies on non-cholesterol sterols in patients with primary hypercholesterolemia by Assmann, Gerd, Kannenberg, Frank, Ramey, Dena R., Musliner, Thomas A., Gutkin, Stephen W., Veltri, Enrico P.

“…ABSTRACT Background: Levels of cholesterol are regulated by its synthesis, absorption, and elimination. Plasma levels of phytosterols (e.g., sitosterol,…”
Get full text

Changes in LDL-C levels and goal attainment associated with addition of ezetimibe to simvastatin, atorvastatin, or rosuvastatin compared with titrating statin monotherapy by Foody, JoAnne M, Toth, Peter P, Tomassini, Joanne E, Sajjan, Shiva, Ramey, Dena R, Neff, David, Tershakovec, Andrew M, Hu, Henry, Tunceli, Kaan

“…Many high-risk coronary heart disease (CHD) patients on statin monotherapy do not achieve guideline-recommended low-density lipoprotein cholesterol (LDL-C)…”
Get full text

TREATMENT PATTERN CHANGES IN HIGH RISK PATIENTS ON STATIN MONOTHERAPY IN A MANAGED CARE SETTING by Jacobson, Terry A, Tunceli, Kaan, Ramey, Dena R, Neff, David R, Kern, David M, Hseih, Hui-Min, Wertz, Debra A, Stephenson, Judith, Marrett, Elizabeth, Simpson, Ross

“…Rates and mean time to 1st and 2nd treatment change were examined in patients who had medical claims for coronary heart disease (CHD), atherosclerotic vascular…”
Get full text

Limitations of real-world treatment with atorvastatin monotherapy for lowering LDL-C in high-risk cardiovascular patients in the US by Marrett, Elizabeth, Zhao, Changgeng, Zhang, Ning Jackie, Zhang, Qiaoyi, Ramey, Dena R, Tomassini, Joanne E, Tershakovec, Andrew M, Neff, David R

“…Guidelines endorse statin therapy for lowering low-density lipoprotein cholesterol (LDL-C) to recommended levels, in patients with cardiovascular disease (CVD)…”
Get full text

The incidence of upper gastrointestinal adverse events in clinical trials of etoricoxib vs. non-selective NSAIDs: an updated combined analysis by Ramey, Dena R., Watson, Douglas J., Yu, Chang, Bolognese, James A., Curtis, Sean P., Reicin, Alise S.

“…Objective: In spite of numerous studies demonstrating the serious gastrointestinal (GI) toxicity associated with non-selective non-steroidal anti-inflammatory…”
Get full text

LOSS OF EARLY GAINS IN LOW-DENSITY LIPOPROTEIN CHOLESTEROL GOAL ATTAINMENT AMONG HIGH RISK PATIENTS by Foody, Joanne M, Sajjan, Shiva, Hu, Henry, Ramey, Dena R, Neff, David, Tershakovec, Andrew M, Tomassini, Joanne E, Tunceli, Kaan

Get full text

LEVERAGING ARTIFICIAL INTELLIGENCE TO FACILITATE PATIENT SCREENING: REVEALING THE INFLUENTIAL CLINICAL FEATURES BEHIND MACHINE LEARNING MODELS FOR PH-COPD by DUBROCK, HILARY M, DEL VALLE, KATHRYN, BARMAN, HANNAH, WAGNER, TYLER, CARLSON, KATHERINE, MANOHARAN, MITHUN, RAMEY, DENA R, RU, BOSHU, COYLE, CATELYN, WEISS, TRACEY

Get full text